Clinical Trial

Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta

Study acronym: PreciSION CF
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 6, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SION-719 when given to people with CF who are already taking Trikafta.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-07
Trial Details
NCT Number NCT07108153
Lead Sponsor Sionna Therapeutics Inc.
Conditions Cystic Fibrosis (CF)
Enrollment 16 participants
Start Date 2025-11-03
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-06